🔎 Trials Near Me

Inicio › Leucemia mielógena aguda › Illinois › Chicago

Ensayos clínicos de Leucemia mielógena aguda en Chicago, IL

27 estudios para Leucemia mielógena aguda buscan participantes en centros de Chicago y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.

Texto oficial del estudio (inglés)

¿Reclutando participantes para un estudio? Destácalo en la parte superior de esta página — $99 por 30 días →

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

ReclutandoFase 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06317649

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

ReclutandoFase 3
  • Northwestern, Chicago
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07007312

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

ReclutandoFase 2
  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Edades de 18 a 59 · Todos los sexos · Actualizado el 9 nov 2026 · NCT05554406

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

ReclutandoFase 3
  • US-Chigago IL-UHCHICAGO, Chicago
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT07223814

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

ReclutandoFase 2
  • University of Chicago Comprehensive Cancer Center, Chicago
Edades de 60 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

ReclutandoEstudio observacionalSe aceptan voluntarios sanos
  • Mount Sinai Hospital Medical Center, Chicago
  • John H Stroger Jr Hospital of Cook County, Chicago
  • University of Illinois, Chicago
  • y 1 más
Edades de 40 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT05334069

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

ReclutandoFase 3
  • University of Chicago Medicine, Chicago
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06852222

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

ReclutandoFase 1
  • University of Chicago Comprehensive Cancer Center, Chicago
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06484062

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

ReclutandoFase 2
  • Northwestern University, Chicago
  • Rush MD Anderson Cancer Center, Chicago
  • University of Illinois, Chicago
  • y 2 más
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT05564390

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

ReclutandoFase 2
  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Edades de 18 a 59 · Todos los sexos · Actualizado el 28 oct 2026 · NCT05554393

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

ReclutandoFase 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 oct 2026 · NCT06672146

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

ReclutandoFase 1/2
  • University of Chicago, Chicago
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 oct 2026 · NCT06969430

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

ReclutandoFase 1/2
  • The University of Chicago Medical Center, Chicago
30 Days · Todos los sexos · Actualizado el 9 oct 2026 · NCT04065399

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

ReclutandoFase 3
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
6 Months – 21 Years · Todos los sexos · Actualizado el 17 sept 2026 · NCT04293562

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

ReclutandoFase 3
  • Lurie Children's Hospital-Chicago, Chicago
Edades de 1 a 25 · Todos los sexos · Actualizado el 4 sept 2026 · NCT07022678

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

ReclutandoFase 1/2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Hasta los 22 · Todos los sexos · Actualizado el 25 ago 2026 · NCT04726241

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

ReclutandoFase 1
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 ago 2026 · NCT06001788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

ReclutandoEstudio observacional
  • Northwestern Memorial Hospital, Chicago
  • Rush University Medical Center, Chicago
  • University of Illinois at Chicago, Chicago
  • y 2 más
Todas las edades · Todos los sexos · Actualizado el 6 jul 2026 · NCT01351545

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

ReclutandoFase 1
  • University of Chicago, Chicago
Edades de 13 en adelante · Todos los sexos · Actualizado el 5 may 2026 · NCT04771572

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

ReclutandoFase 1/2
  • Northwestern University, Chicago
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 abr 2026 · NCT05732103

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

ReclutandoFase 1/2
  • Northwestern, Chicago
Edades de 12 en adelante · Todos los sexos · Actualizado el 24 mar 2026 · NCT04988555

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

ReclutandoFase 1
  • Northwestern Medicine, Chicago
Edades de 12 en adelante · Todos los sexos · Actualizado el 16 mar 2026 · NCT06994676

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

ReclutandoFase 1
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 mar 2026 · NCT05735184

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

ReclutandoFase 1
  • Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2025 · NCT06501196

Más información sobre Leucemia mielógena aguda en MedlinePlus

Ensayos de Leucemia mielógena aguda en otras ciudades

Otros estudios en Chicago

De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.